vs
LESAKA TECHNOLOGIES INC（LSAK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是LESAKA TECHNOLOGIES INC的1.2倍（$207.3M vs $178.7M），LESAKA TECHNOLOGIES INC净利率更高（2.0% vs -62.0%，领先64.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 1.4%），LESAKA TECHNOLOGIES INC自由现金流更多（$-14.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.7%）
莱萨卡科技是一家总部位于南非的金融科技公司，目前同时在纳斯达克交易所与约翰内斯堡证券交易所挂牌上市。公司核心业务聚焦于金融普惠，面向此前金融服务覆盖不足的社区与商户提供各类金融服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LSAK vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $178.7M | $207.3M |
| 净利润 | $3.6M | $-128.6M |
| 毛利率 | 31.4% | — |
| 营业利润率 | 1.2% | -54.7% |
| 净利率 | 2.0% | -62.0% |
| 营收同比 | 1.4% | 25.9% |
| 净利润同比 | 111.2% | 3.5% |
| 每股收益（稀释后） | $0.04 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $178.7M | $207.3M | ||
| Q3 25 | $171.4M | $159.9M | ||
| Q2 25 | $168.5M | $166.5M | ||
| Q1 25 | $161.4M | $139.3M | ||
| Q4 24 | $176.2M | $164.6M | ||
| Q3 24 | $153.6M | $139.5M | ||
| Q2 24 | $146.0M | $147.0M | ||
| Q1 24 | $138.2M | $108.8M |
| Q4 25 | $3.6M | $-128.6M | ||
| Q3 25 | $-4.3M | $-180.4M | ||
| Q2 25 | $-28.4M | $-115.0M | ||
| Q1 25 | $-22.1M | $-151.1M | ||
| Q4 24 | $-32.5M | $-133.2M | ||
| Q3 24 | $-4.5M | $-133.5M | ||
| Q2 24 | $-5.0M | $-131.6M | ||
| Q1 24 | $-4.0M | $-170.7M |
| Q4 25 | 31.4% | — | ||
| Q3 25 | 30.9% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 27.5% | — | ||
| Q4 24 | 25.7% | — | ||
| Q3 24 | 22.6% | — | ||
| Q2 24 | 22.6% | — | ||
| Q1 24 | 22.0% | — |
| Q4 25 | 1.2% | -54.7% | ||
| Q3 25 | 0.2% | -106.9% | ||
| Q2 25 | -16.7% | -64.8% | ||
| Q1 25 | 0.4% | -102.6% | ||
| Q4 24 | 0.3% | -74.3% | ||
| Q3 24 | -0.0% | -94.6% | ||
| Q2 24 | 0.2% | -79.1% | ||
| Q1 24 | 0.6% | -151.9% |
| Q4 25 | 2.0% | -62.0% | ||
| Q3 25 | -2.5% | -112.8% | ||
| Q2 25 | -16.9% | -69.0% | ||
| Q1 25 | -13.7% | -108.5% | ||
| Q4 24 | -18.4% | -80.9% | ||
| Q3 24 | -3.0% | -95.7% | ||
| Q2 24 | -3.4% | -89.5% | ||
| Q1 24 | -2.9% | -156.8% |
| Q4 25 | $0.04 | $-1.28 | ||
| Q3 25 | $-0.05 | $-1.81 | ||
| Q2 25 | $-0.40 | $-1.17 | ||
| Q1 25 | $-0.27 | $-1.57 | ||
| Q4 24 | $-0.40 | $-1.34 | ||
| Q3 24 | $-0.07 | $-1.40 | ||
| Q2 24 | $-0.08 | $-1.52 | ||
| Q1 24 | $-0.06 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.5M | $421.0M |
| 总债务越低越好 | $216.8M | — |
| 股东权益账面价值 | $180.6M | $-80.0M |
| 总资产 | $704.6M | $1.5B |
| 负债/权益比越低杠杆越低 | 1.20× | — |
8季度趋势，按日历期对齐
| Q4 25 | $69.5M | $421.0M | ||
| Q3 25 | $72.2M | $202.5M | ||
| Q2 25 | $76.5M | $176.3M | ||
| Q1 25 | $71.0M | $127.1M | ||
| Q4 24 | $60.6M | $174.0M | ||
| Q3 24 | $49.7M | $150.6M | ||
| Q2 24 | $59.1M | $480.7M | ||
| Q1 24 | $55.2M | $112.3M |
| Q4 25 | $216.8M | — | ||
| Q3 25 | $208.1M | — | ||
| Q2 25 | $200.8M | — | ||
| Q1 25 | $194.7M | — | ||
| Q4 24 | $148.7M | — | ||
| Q3 24 | $148.5M | — | ||
| Q2 24 | $143.2M | — | ||
| Q1 24 | $135.7M | — |
| Q4 25 | $180.6M | $-80.0M | ||
| Q3 25 | $170.4M | $9.2M | ||
| Q2 25 | $161.6M | $151.3M | ||
| Q1 25 | $185.2M | $144.2M | ||
| Q4 24 | $193.3M | $255.0M | ||
| Q3 24 | $184.2M | $346.8M | ||
| Q2 24 | $175.9M | $432.4M | ||
| Q1 24 | $173.1M | $140.3M |
| Q4 25 | $704.6M | $1.5B | ||
| Q3 25 | $652.9M | $1.2B | ||
| Q2 25 | $653.7M | $1.3B | ||
| Q1 25 | $649.2M | $1.3B | ||
| Q4 24 | $640.6M | $1.5B | ||
| Q3 24 | $551.9M | $1.5B | ||
| Q2 24 | $558.5M | $1.6B | ||
| Q1 24 | $551.5M | $1.3B |
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.81× | — | ||
| Q1 24 | 0.78× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | -8.3% | -48.6% |
| 资本支出强度资本支出/营收 | 2.2% | 0.5% |
| 现金转化率经营现金流/净利润 | -2.99× | — |
| 过去12个月自由现金流最近4个季度 | $-15.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-10.9M | $-99.8M | ||
| Q3 25 | $8.9M | $-91.4M | ||
| Q2 25 | $-9.1M | $-108.3M | ||
| Q1 25 | $10.7M | $-166.5M | ||
| Q4 24 | $-9.2M | $-79.3M | ||
| Q3 24 | $-4.1M | $-67.0M | ||
| Q2 24 | $5.7M | $-77.0M | ||
| Q1 24 | $19.2M | $-190.7M |
| Q4 25 | $-14.8M | $-100.8M | ||
| Q3 25 | $4.9M | $-92.7M | ||
| Q2 25 | $-13.2M | $-110.7M | ||
| Q1 25 | $7.8M | $-167.8M | ||
| Q4 24 | $-15.5M | $-79.5M | ||
| Q3 24 | $-8.1M | $-68.6M | ||
| Q2 24 | $937.0K | $-79.0M | ||
| Q1 24 | $16.2M | $-193.9M |
| Q4 25 | -8.3% | -48.6% | ||
| Q3 25 | 2.9% | -58.0% | ||
| Q2 25 | -7.8% | -66.5% | ||
| Q1 25 | 4.9% | -120.5% | ||
| Q4 24 | -8.8% | -48.3% | ||
| Q3 24 | -5.3% | -49.2% | ||
| Q2 24 | 0.6% | -53.7% | ||
| Q1 24 | 11.7% | -178.2% |
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 2.3% | 0.8% | ||
| Q2 25 | 2.4% | 1.5% | ||
| Q1 25 | 1.7% | 1.0% | ||
| Q4 24 | 3.6% | 0.1% | ||
| Q3 24 | 2.6% | 1.2% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 2.1% | 3.0% |
| Q4 25 | -2.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSAK
| Telecom Products And Services | $82.0M | 46% |
| Processing Fees | $37.6M | 21% |
| Enterprise Segment | $14.5M | 8% |
| Rest Of Africa | $10.9M | 6% |
| Technology Products | $8.6M | 5% |
| Insurance Revenue | $7.9M | 4% |
| Lending Revenue | $7.2M | 4% |
| Other | $6.7M | 4% |
| Interest From Customer | $2.1M | 1% |
| Other Products And Services | $1.2M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
